Clinically active Crohn's disease in the presence of a low C-reactive protein

Scandinavian Journal of Gastroenterology

Volumn 41, Issue 3, 2006, Pages 306-311

  Florin, Timothy H J ^a,b,d   Paterson, Ewan W J ^a,b   Fowler, Elizabeth V ^a,c   Radford Smith, Graham L ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MATER HOSPITAL   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d MATER ADULT HOSPITAL   (Australia)

Author keywords

BMI; Body mass index; C reactive protein; CD; Crohn; CRP; Fat wrapping; IBD; Inflammatory indicator; NOD2; Phenotype; Vienna classification

Indexed keywords

C REACTIVE PROTEIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15;

ANAMNESIS; APPENDECTOMY; ARTICLE; BODY FAT; BODY MASS; COLON DISEASE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE MARKER; FEMALE; HUMAN; ILEUM DISEASE; ILEUM RESECTION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CHILD; CROHN DISEASE; DNA; FEMALE; GENOTYPE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NOD2 SIGNALING ADAPTOR PROTEIN; PROGNOSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 33644589943     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520500217118     Document Type: Article

References (30)

1. Clos TD, Mold C. The role of C-reactive protein in the resolution of bacterial infection. Curr Opin Infect Dis 2001;14:289-93.
2. Darlington G, Wilson D, Lachman L. Monocyte-conditioned medium, interleukin-1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro. J Cell Biol 1986;103:787-93.
3. Best W, Becktel J, Singleton J, Kern Jr F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
4. Goebell H, Wienbeck M, Schomerus H, Malchow H. Evaluation of the Crohn's Disease Activity Index (CDAI) and the Dutch Index for severity and activity of Crohn's disease. An analysis of the data from the European Cooperative Crohn's Disease Study. Med Klin (Munich) 1990;85:573-6.
5. Gomes P, Boulau CD, Smith C, Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986;27:92-5.
6. Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne J, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 1994;35:231-5.
7. Schreiber S, Fedorak R, Rutgeerts P, Innes A, Patel J. CDP870, a pegylated humanised anti-TNF antibody fragment, offers particular benefit to Crohn's disease patients with elevated C-reactive protein. Gut ; S6 2003;52:A4.
8. Rutgeerts P, Colombel J, Enns R, Feagan B, Hanauer S, Lawrence I, et al. Subanalyses from a phase 3 study on the evaluation of natalizumab in active Crohn's disease (ENACT-1). Gut ; S6 2003;52:A239.
9. Targan S, Hanauer S, van Deventer S, Mayer L, Present D, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
10. Louis E, Vermeire S, Rutgeerts P, Vos MD, Gossum AV, Pescatore P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with (308 TNF gene polymorphism. Scand J Gastroenterol 2002;37:818-24.
11. Lennard-Jones J. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989;170 Suppl:2-6.
12. Gasche C, Alizadeh B, Pena A. Genotype-phenorype correlations: how many disorders constitute inflammatory bowel disease? Eur J Gastroenterol Hepatol 2003;15:599-606.
13. Hugot J, Chamaillard M, Zouali H, Lesage S, Cezard J, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
14. Ogura Y, Bonen D, Inohara N, Nicolae D, Chen F, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
15. Cavanaugh J, Adams K, Quak E, Bryce M, O'Callaghan N, Rodgers H, et al. CARD15/NOD2 risk alleles in the development of Crohn's disease in the Australian population. Ann Hum Genet 2003;67:35-41.
16. Olaison G, Smedh K, Sjodahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992;33:331-5.
17. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-50.
18. Lautenbach E, Berlin JA, Lichtenstein GR. Risk factors for early postoperative recurrence of Crohn's disease. Gastroenterology 1998;115:259-67.
19. Borley NR, Mortensen NJ, Chaudry MA, Mohammed S, Warren BF, Geoghan BD, et al. Recurrence after abdominal surgery for Crohn's disease: relationship to disease site and surgical procedure. Dis Colon Rectum 2002;45:377-83.
20. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002;122:854-66.
21. Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002;70:845-57.
22. Greenfield J, Samaras K, Jenkins A, Kelly P, Spector T, Gallimore J, et al. Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation 2004;109:3022-8.
23. Maachi M, Pieroni L, Bruckert E, Jardel C, Fellahi S, Hainque B, et al. Systemic low-grade inflammation is related to both circulating and adipose tissue TNFalpha, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord 2004;28:993-7.
24. Williams M, Williams S, Milne B, Hancox R, Poulton R. Association between C-reactive protein, metabolic cardiovascular risk factors, obesity and oral contraceptive use in young adults. Int J Obes Relat Metab Disord 2004;28:998-1003.
25. Desreumaux P, Ernst O, Geboes K, Gambiez L, Berrebi D, Muller-Alouf H, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 1999;117:73-81.
26. Weisberg S, McCann D, Desai M, Rosenbaum M, Leibel R, Jr AF. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808.
27. Blain A, Cattan S, Beaugerie L, Carbonnel F, Gendre JP, Cosnes J. Crohn's disease clinical course and severity in obese patients. Clin Nutr 2002;21:51-7.
28. Smedh K, Olaison G, Nystrom P, Sjodahl R. Intraoperative enteroscopy in Crohn's disease. Br J Surg 1993;80:897-900.
29. Sheehan A, Warren B, Gear M, Shepherd N. Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice. Br J Surg 1992;79:955-8.
30. Borley N, Mortensen N, Jewell D, Warren B. The relationship between inflammatory and serosal connective tissue changes in ileal Crohn's disease: evidence for a possible causal link. J Pathol 2000;190:196-202.